| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (NCT07594548) | Northwestern University | 2027-09-09 |
| A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study (NCT07517211) | Jonsson Comprehensive Cancer Center | 2026-12-01 |
| Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial (NCT07439484) | Jonsson Comprehensive Cancer Center | 2026-09-01 |
| Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers (NCT05296005) | Ohio State University Comprehensive Cancer Center | 2025-12-31 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence (NCT07139951) | Mayo Clinic | 2025-12-03 |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors (NCT06364410) | National Cancer Institute (NCI) | 2025-02-03 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (NCT06203600) | National Cancer Institute (NCI) | 2024-06-24 |
| Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (NCT05836584) | National Cancer Institute (NCI) | 2023-12-06 |
| Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (NCT06078709) | Mayo Clinic | 2023-11-20 |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors (NCT05733000) | Northwestern University | 2023-03-08 |
| Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (NCT05651594) | Roswell Park Cancer Institute | 2023-03-07 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (NCT05677490) | Alliance for Clinical Trials in Oncology | 2023-01-31 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (NCT05269381) | Mayo Clinic | 2022-03-31 |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153) | M.D. Anderson Cancer Center | 2022-02-14 |
| Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (NCT04929392) | City of Hope Medical Center | 2022-01-25 |
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (NCT04391049) | NRG Oncology | 2021-12-02 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (NCT04535401) | National Cancer Institute (NCI) | 2021-08-13 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760) | Academic and Community Cancer Research United | 2021-06-16 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (NCT04460937) | National Cancer Institute (NCI) | 2021-04-09 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (NCT03641313) | National Cancer Institute (NCI) | 2020-11-16 |
| Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer (NCT04522336) | M.D. Anderson Cancer Center | 2020-09-16 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT04097028) | Roswell Park Cancer Institute | 2019-12-20 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (NCT03801876) | NRG Oncology | 2019-06-26 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (NCT03604991) | National Cancer Institute (NCI) | 2019-05-03 |
| Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma (NCT03784326) | M.D. Anderson Cancer Center | 2019-02-19 |
| Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (NCT03776487) | M.D. Anderson Cancer Center | 2019-01-07 |